Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

Douglas Research Advisory

Equity Capital Markets

<ul>
<li>On 29 August, Gemvax &amp; Kael (082270 KS) (Gemvax) announced a rights offering capital raise of 249 billion won.</li>
<li>Gemvax will issue 6.7 million new shares in this rights offering, representing 16% of its outstanding shares. </li>
<li>The expected rights offering price is 37,100 won which is 13.4% lower than current price. We are negative on this rights offering. </li>
</ul>


On 29 August, Gemvax &amp; Kael (082270 KS) (Gemvax) announced a rights offering capital raise of 249 billion won.
Gemvax will issue 6.7 million new shares in this rights offering, representing 16% of its outstanding shares. 
The expected rights offering price is 37,100 won which is 13.4% lower than current price. We are negative on this rights offering. 


Gemvax & Kael - Rights Offering of 249 Billion Won